Pharmacopeia Software Division Demonstrates New Chemistry Software At American Chemical Society Meeting

Apr 03, 2001, 01:00 ET from Pharmacopeia, Inc.

    PRINCETON, N.J., April 3 /PRNewswire/ -- The software business of
 Pharmacopeia, Inc. (Nasdaq:   PCOP) demonstrated a wide range of new scientific
 software and technology at this week's American Chemical Society Meeting in
 San Diego.  Pharmacopeia announced yesterday that this business, formed by
 combining Molecular Simulations Inc. (MSI), Oxford Molecular Ltd., Synopsys
 Scientific Systems Ltd., and the Genetics Computer Group (GCG), is to operate
 as Accelrys Inc. from June 1, 2001.
     As well as significantly strengthening its comprehensive portfolio for
 pharmaceutical discovery and chemical development, the products spotlighted
 represent a significant step in developing a next generation software
 platform.  They illustrate the benefits of integrating the technologies,
 knowledge, and ideas of some of the world's most-respected scientific software
 developers.
     Dr. Michael Stapleton, Chief Operating Officer for Accelrys explained the
 company's product strategy, "We will continue to extend our capabilities
 across a product range encompassing genomics, structural biology, and the
 design and development of drugs, materials, and chemical processes.  Across
 these activities, we will facilitate the management and use of chemical and
 biological information.  We will integrate our technologies with each other,
 with personal productivity tools and with corporate IT infrastructures.  Our
 vision is of an integrated software platform supporting enterprise-wide R&D
 decisions."
 
     MedChem Explorer 2.0
     Consistent with this vision, Accelrys introduced MedChem Explorer 2.0, an
 evolution of WebLab.  A subset of Accelrys modeling tools is now available in
 a standard Windows(R) user interface on desktop PCs, networked with other
 computational experts and experimentalists, and integrated with informatics,
 desktop productivity tools, and the corporate IT infrastructure.  Future
 products will increase the range of technology accessible within such an
 environment.
     MedChem Explorer 2.0 helps medicinal chemistry teams to accelerate the
 search for high quality lead compounds in the drug discovery process.  The
 product integrates expert tools for pharmacophore modeling and database mining
 on the PC and introduces Query Fit, a powerful lead optimization tool that
 fits, maps, and compares the conformation of an input molecule to a
 pharmacophore hypothesis.
 
     Materials Studio(TM)
     Materials Studio is Accelrys' PC-based software environment for materials
 research.  The brand was launched in 2000 and is extended through the addition
 of Equilibria, a new Materials Studio product for determining hydrocarbon
 phase diagrams.  Equilibria brings the power of the Gibbs ensemble method to
 the desktop, accelerating chemical process design.  The application is of
 special value to chemists and chemical engineers in the petrochemical and
 related industries.
 
     Cheminformatics
     The integration of the Oxford Molecular and Synopsys range of products has
 created a new force in cheminformatics.  Accelrys continues to combine and to
 develop the Accord and RS3 Discovery technologies.
     RS3 Inventory(TM) is the first in a new range of chemistry workflow
 products.  RS3 Inventory provides effective management of discovery inventory,
 by supporting high throughput processes for chemistry and screening to
 increase productivity and reduce costs.  Using RS3 Inventory, scientists, team
 leaders and stockroom managers know what compounds are available, when they
 need them.  The latest versions of the RS3 Discovery(TM) HTS and OMMM(TM)
 screening workflow products are also being launched at ACS, along with the new
 release of TOPKAT(TM) for predictive toxicology assessment.
     The Accord Grid Control is a new product allowing developers to display
 and manipulate chemical objects in a grid format alongside associated text and
 numerical data, creating a lightweight chemical spreadsheet component that can
 be embedded and used in custom applications.
 
     Expert Modeling Technology
     Accelrys continues to maintain and advance its market-leading modeling
 technology for expert computational chemists.  Cerius2 version 4.6 will be
 released in the summer of 2001.  The new module, C2.ADME, provides
 computational models for the prediction of absorption, distribution,
 metabolism, and excretion (ADME), properties derived from chemical structures.
 C2.ADME is designed to allow scientists to reduce drug discovery costs without
 increasing time to market.
 
     Pharmacopeia (www.pharmacopeia.com) is a leader in enabling science and
 technology that improves and accelerates drug discovery and chemical
 development.  Pharmacopeia's software segment develops and commercializes gene
 sequence analyses, molecular modeling and simulation, cheminformatics,
 bioinformatics, workflow, and decision support software for the life sciences
 and materials research.  It also provides consulting services to its customers
 in drug discovery and chemical development.  Pharmacopeia's Drug Discovery
 segment integrates proprietary small molecule combinatorial and medicinal
 chemistry, high-throughput screening, in-vitro pharmacology, computational
 methods, and informatics to discover and optimize lead compounds and to
 accelerate customers' drug discovery efforts.  Pharmacopeia employs
 approximately 750 people, generated 2000 revenues of approximately
 $119 million, and is headquartered in Princeton, NJ.
 
     When used anywhere in this document, the words "expects", "believes",
 "anticipates", "estimates" and similar expressions are intended to identify
 forward-looking statements.  Pharmacopeia has based these forward-looking
 statements on its current expectations about future events.  Such statements
 are subject to risks and uncertainties including, but not limited to, the
 successful implementation of Pharmacopeia's strategic plan, the acceptance of
 new products, the obsolescence of existing products, the resolution of
 existing and potential future patent issues, additional competition, changes
 in economic conditions, and other risks described in documents Pharmacopeia
 has filed with the Securities and Exchange Commission, including its most
 recent report on Form 10-K and subsequent reports on Form 10-Q.  All forward-
 looking statements in this document are qualified entirely by the cautionary
 statements included in this document and such filings.  These risks and
 uncertainties could cause actual results to differ materially from results
 expressed or implied by forward-looking statements contained in this document.
 These forward-looking statements speak only as of the date of this document.
 Pharmacopeia disclaims any undertaking to publicly update or revise any
 forward-looking statements contained herein to reflect any change in its
 expectations with regard thereto or any change in events, conditions or
 circumstances on which any such statement is based.
 
 

SOURCE Pharmacopeia, Inc.
    PRINCETON, N.J., April 3 /PRNewswire/ -- The software business of
 Pharmacopeia, Inc. (Nasdaq:   PCOP) demonstrated a wide range of new scientific
 software and technology at this week's American Chemical Society Meeting in
 San Diego.  Pharmacopeia announced yesterday that this business, formed by
 combining Molecular Simulations Inc. (MSI), Oxford Molecular Ltd., Synopsys
 Scientific Systems Ltd., and the Genetics Computer Group (GCG), is to operate
 as Accelrys Inc. from June 1, 2001.
     As well as significantly strengthening its comprehensive portfolio for
 pharmaceutical discovery and chemical development, the products spotlighted
 represent a significant step in developing a next generation software
 platform.  They illustrate the benefits of integrating the technologies,
 knowledge, and ideas of some of the world's most-respected scientific software
 developers.
     Dr. Michael Stapleton, Chief Operating Officer for Accelrys explained the
 company's product strategy, "We will continue to extend our capabilities
 across a product range encompassing genomics, structural biology, and the
 design and development of drugs, materials, and chemical processes.  Across
 these activities, we will facilitate the management and use of chemical and
 biological information.  We will integrate our technologies with each other,
 with personal productivity tools and with corporate IT infrastructures.  Our
 vision is of an integrated software platform supporting enterprise-wide R&D
 decisions."
 
     MedChem Explorer 2.0
     Consistent with this vision, Accelrys introduced MedChem Explorer 2.0, an
 evolution of WebLab.  A subset of Accelrys modeling tools is now available in
 a standard Windows(R) user interface on desktop PCs, networked with other
 computational experts and experimentalists, and integrated with informatics,
 desktop productivity tools, and the corporate IT infrastructure.  Future
 products will increase the range of technology accessible within such an
 environment.
     MedChem Explorer 2.0 helps medicinal chemistry teams to accelerate the
 search for high quality lead compounds in the drug discovery process.  The
 product integrates expert tools for pharmacophore modeling and database mining
 on the PC and introduces Query Fit, a powerful lead optimization tool that
 fits, maps, and compares the conformation of an input molecule to a
 pharmacophore hypothesis.
 
     Materials Studio(TM)
     Materials Studio is Accelrys' PC-based software environment for materials
 research.  The brand was launched in 2000 and is extended through the addition
 of Equilibria, a new Materials Studio product for determining hydrocarbon
 phase diagrams.  Equilibria brings the power of the Gibbs ensemble method to
 the desktop, accelerating chemical process design.  The application is of
 special value to chemists and chemical engineers in the petrochemical and
 related industries.
 
     Cheminformatics
     The integration of the Oxford Molecular and Synopsys range of products has
 created a new force in cheminformatics.  Accelrys continues to combine and to
 develop the Accord and RS3 Discovery technologies.
     RS3 Inventory(TM) is the first in a new range of chemistry workflow
 products.  RS3 Inventory provides effective management of discovery inventory,
 by supporting high throughput processes for chemistry and screening to
 increase productivity and reduce costs.  Using RS3 Inventory, scientists, team
 leaders and stockroom managers know what compounds are available, when they
 need them.  The latest versions of the RS3 Discovery(TM) HTS and OMMM(TM)
 screening workflow products are also being launched at ACS, along with the new
 release of TOPKAT(TM) for predictive toxicology assessment.
     The Accord Grid Control is a new product allowing developers to display
 and manipulate chemical objects in a grid format alongside associated text and
 numerical data, creating a lightweight chemical spreadsheet component that can
 be embedded and used in custom applications.
 
     Expert Modeling Technology
     Accelrys continues to maintain and advance its market-leading modeling
 technology for expert computational chemists.  Cerius2 version 4.6 will be
 released in the summer of 2001.  The new module, C2.ADME, provides
 computational models for the prediction of absorption, distribution,
 metabolism, and excretion (ADME), properties derived from chemical structures.
 C2.ADME is designed to allow scientists to reduce drug discovery costs without
 increasing time to market.
 
     Pharmacopeia (www.pharmacopeia.com) is a leader in enabling science and
 technology that improves and accelerates drug discovery and chemical
 development.  Pharmacopeia's software segment develops and commercializes gene
 sequence analyses, molecular modeling and simulation, cheminformatics,
 bioinformatics, workflow, and decision support software for the life sciences
 and materials research.  It also provides consulting services to its customers
 in drug discovery and chemical development.  Pharmacopeia's Drug Discovery
 segment integrates proprietary small molecule combinatorial and medicinal
 chemistry, high-throughput screening, in-vitro pharmacology, computational
 methods, and informatics to discover and optimize lead compounds and to
 accelerate customers' drug discovery efforts.  Pharmacopeia employs
 approximately 750 people, generated 2000 revenues of approximately
 $119 million, and is headquartered in Princeton, NJ.
 
     When used anywhere in this document, the words "expects", "believes",
 "anticipates", "estimates" and similar expressions are intended to identify
 forward-looking statements.  Pharmacopeia has based these forward-looking
 statements on its current expectations about future events.  Such statements
 are subject to risks and uncertainties including, but not limited to, the
 successful implementation of Pharmacopeia's strategic plan, the acceptance of
 new products, the obsolescence of existing products, the resolution of
 existing and potential future patent issues, additional competition, changes
 in economic conditions, and other risks described in documents Pharmacopeia
 has filed with the Securities and Exchange Commission, including its most
 recent report on Form 10-K and subsequent reports on Form 10-Q.  All forward-
 looking statements in this document are qualified entirely by the cautionary
 statements included in this document and such filings.  These risks and
 uncertainties could cause actual results to differ materially from results
 expressed or implied by forward-looking statements contained in this document.
 These forward-looking statements speak only as of the date of this document.
 Pharmacopeia disclaims any undertaking to publicly update or revise any
 forward-looking statements contained herein to reflect any change in its
 expectations with regard thereto or any change in events, conditions or
 circumstances on which any such statement is based.
 
 SOURCE  Pharmacopeia, Inc.